NasdaqGS:DNLIBiotechs
Assessing Denali Therapeutics (DNLI) Valuation After Recent Share Pullback And Pipeline Growth Expectations
Recent share performance and business profile
Denali Therapeutics (DNLI) has been on many watchlists after a mixed stretch in the share price, with a loss of about 10% over the past month but a gain of roughly 13% over the past 3 months.
At a last close of US$19.29 and a market value of about US$3.1b, Denali Therapeutics develops treatments targeting neurodegenerative and lysosomal storage diseases, including programs for Parkinson’s disease, frontotemporal dementia, Hunter Syndrome, and...